The use of low-value procedures, or those that would not be expected to require hospitalization, was linked to more hospital-acquired complications in a study published in JAMA Internal Medicine. The ...
If the novel factor XI inhibitor abelacimab reaches the market for patients with atrial fibrillation (AF) who require anticoagulation, it may not be necessary to interrupt treatment ahead of invasive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback